A record of what HDFC Securities said publicly, with the source. Not advice.
“HDFC Securities recommends adding Alkem Laboratories shares with a target price of Rs 5,700, up from the current market price of Rs 4,932. The rationale suggests moderate sales growth, with ~8% growth in India formulation and international business (ex-US) partly offsetting muted US business (-1% QoQ). Gross margin is expected to improve YoY, but higher costs for growth initiatives will keep EBITDA under pressure.”
HDFC Securities’s track record (trackable calls only): 78 graded calls · 95% CI 43–64%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹5,700, as stated.
Window: 12 months, the default when no time frame is stated.
The target ₹5,700 was reached on a close. Hit.
The grader’s working: R4 TARGET_CALL: entered ₹5000.4 on 2025-04-21 (next trading session's close); target ₹5700 reached at close ₹5767.5 on 2025-11-12. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.